logo BDSP

Base documentaire

  1. Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections.

    Article - En anglais

    Costs involved in using piperacillin 4 g/tazobactam 500 mg, given as intermittent intravenous infusions every 8 hours, were compared with those for imipenem/cilastatin 500 mg, given as intermittent intravenous infusions every 6 hours, for the treatment of patients with gangrenous or perforated appendicitis.

    A total of 88 patients were included in our cost analyses : 42 patients in the piperacillin/tazobactam group and 46 patients in the imipenem/cilastatin group.

    Durations (mean±SD) of antibiotic therapies were 7.8±3.3 days and 7.1±2.6 days for the piperacillin/tazobactam and imipenem/cilastatin groups, respectively.

    No statistical significance was found for the difference in duration of therapy (P=0.376).

    Total drug treatment costs were $538.83±$385.33 for the piperacillin/tazobactam group and $687.66±$345.37 for the imipenem/cilastatin group.

    This difference in treatment cost was statistically significant (P=0.0001).

    The need for laboratory tests and the use of other medications were not different between the two groups.

    Total hospital-days charges were higher for the piperacillin/tazobactam group ($18,339.76±$6090.38) compared with the imipenem/cilastatin group ($16,150.00±$5088.60) (P=0.052).

    These findings suggest that length of hospital stay should be the economic focus of antibiotic therapy.

    Mots-clés Pascal : Pipéracilline, Tazobactam, Imipénem, Cilastatine, Association médicamenteuse, Bactériose, Infection, Abdomen, Homme, Etude comparative, Analyse coût efficacité, Antibactérien, Antibiotique, Voie intraveineuse, Pénicilline dérivé, Abdomen pathologie, Hôpital, Chimiothérapie, Traitement, Carbapénème dérivé

    Mots-clés Pascal anglais : Drug combination, Bacteriosis, Infection, Abdomen, Human, Comparative study, Cost efficiency analysis, Antibacterial agent, Antibiotic, Intravenous administration, Penicillin derivatives, Abdominal disease, Hospital, Chemotherapy, Treatment

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 95-0208597

    Code Inist : 002B02S02. Création : 09/06/1995.